Skip to content

Discovery and validation of genetic markers to establish effective indications of anti-osteoporotic drugs

Discovery and validation of genetic markers to establish effective indications of anti-osteoporotic drugs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0000426
Enrollment
6604
Registered
2012-04-30
Start date
2011-11-23
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who visit Asan Medical Center for osteoporosis and give the informed consent. Patients with measurement of bone mineral density (BMD) for osteoporosis (Classification of case / control group by BMD result) Wahout peroid: Two years using agents more than 6 months against osteoporosis

Exclusion criteria

Exclusion criteria: 1. Subjects within wash-out period 2. Secondary osteoporosis: Disorders strongly associated with osteoporosis. These include rheumatoid arthritis, untreated long-standing hyperthyroidism or Graves' disease, chronic liver disease, hyperparathyroidism, and parathyroid adenoma 3. Other conditions were not suitable in cohort study: Chronic renal failure, active malignany, and transplantation

Design outcomes

Primary

MeasureTime frame
Association between novel discovered SNP with osteoporosis or osteoporotic fracture risk

Secondary

MeasureTime frame
Association between novel discovered SNP with bone mineral density ;Association between novel discovered SNP with changes of bone mineral density ;Effect of novel discovered SNP on changes of bone mineral density according to treatment methods

Countries

Korea, Republic of

Contacts

Public ContactSeung Hun Lee

Asan Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026